Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country
PLOS One · 03.04.2026 · 21 (4) · e0345212
DOI: 10.1371/journal.pone.0345212 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 03.04.2026. Verfasst von Thang Xuan Do und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Management and Pharmacoeconomics, Hanoi University of Pharmacy, Hanoi, Vietnam. Hauptthemen laut MEDLINE: Phenylurea Compounds, Carcinoma, Hepatocellular, Sorafenib, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vinhealth.
Abstract (Originalsprache)
Objectives
To evaluate cost-effectiveness of lenvatinib compared with sorafenib as first-line treatment in unresectable hepatocellular carcinoma (HCC) patients in Vietnam from a perspective of the public third-party payer.
Methods
A three-health state partitioned survival model was developed to compare costs and health outcomes of lenvatinib and sorafenib in unresectable advanced HCC patients over a 10-year time horizon, using a cycle length of 28-day. Clinical data on efficacy and safety of lenvatinib and sorafenib from the REFLECT trial was used to extrapolate outcomes beyond the follow-up period, while medication costs and health care resources were estimated based on local data and clinical experts’ consultations. A discount rate of 3% was applied to both costs and outcomes. Parameter uncertainty was explored using one-way sensitivity analysis and probabilistic sensitivity analysis. The impact of different time horizons and different approaches to extrapolate survival time were examined in scenario analyses.
Results
In unresectable HCC patients, lenvatinib gained more 0.28 life-years (LYs) equaling to 0.21 quality-adjusted life-years (QALYs) compared with sorafenib. Without consideration of reimbursement rate for all medications and co-insurance, usage of lenvatinib led to an increase of 3,451.3 USD. Therefore, lenvatinib was not cost-effective compared with sorafenib, with an incremental cost-effectiveness ratio (ICER) of 16,114.5 USD/QALY. However, if lenvatinib was reimbursed at the same rate as sorafenib (50%), it became cost-effective, with an ICER of 8,307.6 USD/QALY. Results from the base-case analysis were robust in different sensitivity analyses.
Conclusions
With a significant improvement in progression-free survival, lenvatinib gained more LYs and QALYs compared with sorafenib. At the same reimbursement rate of sorafenib of 50%, lenvatinib was cost-effective from the perspective of the third-party payer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Management and Pharmacoeconomics, Hanoi University of Pharmacy, Hanoi, Vietnam.
- University of Health Sciences, Vietnam National University Ho Chi Minh City, Ho Chi Minh, Vietnam.
ORCID-Profile: Thang Xuan Do, Ha Thi Nguyen, Phuong Thi Lan Nguyen
Förderung
- Vinhealth
Zitieren
APA
Do, T. X., Nguyen, H. T., Nguyen, P. T. L., Kieu, M. T. T., Duong, T. V., & Pham, V. N. H. (2026). Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country. PLOS One, 21(4), e0345212. https://doi.org/10.1371/journal.pone.0345212
Vancouver
Do TX, Nguyen HT, Nguyen PTL, Kieu MTT, Duong TV, Pham VNH. Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country. PLOS One. 2026;21(4):e0345212. doi:10.1371/journal.pone.0345212
BibTeX
@article{Do2026,
author = {Do, Thang Xuan and Nguyen, Ha Thi and Nguyen, Phuong Thi Lan and Kieu, Mai Thi Tuyet and Duong, Tuan Viet and Pham, Van Nu Hanh},
title = {Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {4},
pages = {e0345212},
doi = {10.1371/journal.pone.0345212}
}
EUVIMED